These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

310 related items for PubMed ID: 32814461

  • 21. Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells?
    Kalunian KC.
    Lupus; 2016 Sep; 25(10):1097-101. PubMed ID: 27497254
    [Abstract] [Full Text] [Related]

  • 22. A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.
    Kalunian KC, Furie R, Morand EF, Bruce IN, Manzi S, Tanaka Y, Winthrop K, Hupka I, Zhang LJ, Werther S, Abreu G, Hultquist M, Tummala R, Lindholm C, Al-Mossawi H.
    Arthritis Rheumatol; 2023 Feb; 75(2):253-265. PubMed ID: 36369793
    [Abstract] [Full Text] [Related]

  • 23. Long-Term Safety and Efficacy of Anifrolumab in Adults With Systemic Lupus Erythematosus: Results of a Phase II Open-Label Extension Study.
    Chatham WW, Furie R, Saxena A, Brohawn P, Schwetje E, Abreu G, Tummala R.
    Arthritis Rheumatol; 2021 May; 73(5):816-825. PubMed ID: 33225631
    [Abstract] [Full Text] [Related]

  • 24. Modulation of Cardiometabolic Disease Markers by Type I Interferon Inhibition in Systemic Lupus Erythematosus.
    Casey KA, Smith MA, Sinibaldi D, Seto NL, Playford MP, Wang X, Carlucci PM, Wang L, Illei G, Yu B, Wang S, Remaley AT, Mehta NN, Kaplan MJ, White WI.
    Arthritis Rheumatol; 2021 Mar; 73(3):459-471. PubMed ID: 32909675
    [Abstract] [Full Text] [Related]

  • 25. Anifrolumab for the treatment of active systemic lupus erythematosus: a meta-analysis of randomized controlled trials.
    Lee YH, Song GG.
    Z Rheumatol; 2021 Dec; 80(10):988-994. PubMed ID: 33216191
    [Abstract] [Full Text] [Related]

  • 26. Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials.
    Bruce IN, van Vollenhoven RF, Morand EF, Furie RA, Manzi S, White WB, Abreu G, Tummala R.
    Rheumatology (Oxford); 2023 Apr 03; 62(4):1526-1534. PubMed ID: 36018235
    [Abstract] [Full Text] [Related]

  • 27. Anifrolumab in systemic lupus erythematosus.
    Loncharich MF, Robertson I.
    Drugs Today (Barc); 2023 Feb 03; 59(2):53-61. PubMed ID: 36811405
    [Abstract] [Full Text] [Related]

  • 28. Anifrolumab: First Approval.
    Deeks ED.
    Drugs; 2021 Oct 03; 81(15):1795-1802. PubMed ID: 34554438
    [Abstract] [Full Text] [Related]

  • 29. Exposure-response analysis for selection of optimal dosage regimen of anifrolumab in patients with systemic lupus erythematosus.
    Chia YL, Santiago L, Wang B, Kuruvilla D, Wang S, Tummala R, Roskos L.
    Rheumatology (Oxford); 2021 Dec 01; 60(12):5854-5862. PubMed ID: 33629110
    [Abstract] [Full Text] [Related]

  • 30. Biological drugs for systemic lupus erythematosus or active lupus nephritis and rates of infectious complications. Evidence from large clinical trials.
    Steiger S, Ehreiser L, Anders J, Anders HJ.
    Front Immunol; 2022 Dec 01; 13():999704. PubMed ID: 36211360
    [Abstract] [Full Text] [Related]

  • 31. What Does It Mean to Be a British Isles Lupus Assessment Group-Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials.
    Furie R, Morand EF, Bruce IN, Isenberg D, van Vollenhoven R, Abreu G, Pineda L, Tummala R.
    Arthritis Rheumatol; 2021 Nov 01; 73(11):2059-2068. PubMed ID: 33913260
    [Abstract] [Full Text] [Related]

  • 32. Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab.
    Tang W, Tummala R, Almquist J, Hwang M, White WI, Boulton DW, MacDonald A.
    Clin Pharmacokinet; 2023 May 01; 62(5):655-671. PubMed ID: 37148484
    [Abstract] [Full Text] [Related]

  • 33. Belimumab versus anifrolumab in adults with systemic lupus erythematosus: an indirect comparison of clinical response at 52 weeks.
    Neupane B, Shukla P, Slim M, Martin A, Petri M, Bertsias GK, Kim AHJ, Fanouriakis A, Levy RA, Chauhan D, Ballew N.
    Lupus Sci Med; 2023 May 01; 10(1):. PubMed ID: 37147022
    [Abstract] [Full Text] [Related]

  • 34. [Pharmacological actions of anifrolumab (Saphnelo®) and clinical trial results as a treatment for systemic lupus erythematosus].
    Ueha T, Kusuda M, Shibata S, Hirata M, Ozaki N.
    Nihon Yakurigaku Zasshi; 2022 May 01; 157(4):271-279. PubMed ID: 35781459
    [Abstract] [Full Text] [Related]

  • 35. Biologics targeting type I interferons in SLE: A meta-analysis and systematic review of randomised controlled trials.
    Koh JWH, Ng CH, Tay SH.
    Lupus; 2020 Dec 01; 29(14):1845-1853. PubMed ID: 32960720
    [Abstract] [Full Text] [Related]

  • 36. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE).
    Kalunian KC, Merrill JT, Maciuca R, McBride JM, Townsend MJ, Wei X, Davis JC, Kennedy WP.
    Ann Rheum Dis; 2016 Jan 01; 75(1):196-202. PubMed ID: 26038091
    [Abstract] [Full Text] [Related]

  • 37. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study.
    Khamashta M, Merrill JT, Werth VP, Furie R, Kalunian K, Illei GG, Drappa J, Wang L, Greth W, CD1067 study investigators.
    Ann Rheum Dis; 2016 Nov 01; 75(11):1909-1916. PubMed ID: 27009916
    [Abstract] [Full Text] [Related]

  • 38. Indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus.
    Bruce IN, Golam S, Steenkamp J, Wang P, Worthington E, Desta B, Psachoulia K, Erhardt W, Tummala R.
    J Comp Eff Res; 2022 Jul 01; 11(10):765-777. PubMed ID: 35546484
    [Abstract] [Full Text] [Related]

  • 39. Anifrolumab for treatment of refractory cutaneous lupus erythematosus.
    Blum FR, Sampath AJ, Foulke GT.
    Clin Exp Dermatol; 2022 Nov 01; 47(11):1998-2001. PubMed ID: 35844070
    [Abstract] [Full Text] [Related]

  • 40. Efficacy and Safety of Epratuzumab in Moderately to Severely Active Systemic Lupus Erythematosus: Results From Two Phase III Randomized, Double-Blind, Placebo-Controlled Trials.
    Clowse ME, Wallace DJ, Furie RA, Petri MA, Pike MC, Leszczyński P, Neuwelt CM, Hobbs K, Keiserman M, Duca L, Kalunian KC, Galateanu C, Bongardt S, Stach C, Beaudot C, Kilgallen B, Gordon C, EMBODY Investigator Group.
    Arthritis Rheumatol; 2017 Feb 01; 69(2):362-375. PubMed ID: 27598855
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 16.